Clinical trials: Status Epilepticus
Refractory Status Epilepticus
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED)…
- Trial name
- NCT05814523
- Testing
- Ganaxolone, Standard of care
- Where
- 52 sites in Austria, Belgium and 14 more
- Sponsor
- Marinus Pharmaceuticals
Status Epilepticus
Randomized Therapy In Status Epilepticus
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
- Trial name
- RAISE (NCT04391569)
- Testing
- Ganaxolone
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Marinus Pharmaceuticals